Literature DB >> 26700959

Role of Phosphatidic Acid Phosphatase Domain Containing 2 in Squalestatin 1-Mediated Activation of the Constitutive Androstane Receptor in Primary Cultured Rat Hepatocytes.

Asmita Pant1, Thomas A Kocarek2.   

Abstract

Farnesyl pyrophosphate (FPP) is a branch-point intermediate in the mevalonate pathway that is normally converted mainly to squalene by squalene synthase in the first committed step of sterol biosynthesis. Treatment with the squalene synthase inhibitor squalestatin 1 (SQ1) causes accumulation of FPP, its dephosphorylated metabolite farnesol, and several oxidized farnesol-derived metabolites. In addition, SQ1 treatment of primary cultured rat hepatocytes increases CYP2B expression through a mechanism that requires FPP synthesis and activation of the constitutive androstane receptor (CAR). Because direct farnesol treatment also increases CYP2B expression, it seems likely that SQ1-mediated CAR activation requires FPP dephosphorylation to farnesol. The lipid phosphatase, phosphatidic acid phosphatase domain containing 2 (PPAPDC2), was recently reported to catalyze FPP dephosphorylation. We therefore determined the effect of overexpressing or knocking down PPAPDC2 on SQ1-mediated CAR activation in primary cultured rat hepatocytes. Cotransfection of rat hepatocytes with a plasmid expressing rat or human PPAPDC2 enhanced SQ1-mediated activation of a CAR-responsive reporter by 1.7- or 2.4-fold over the SQ1-mediated activation that was produced when hepatocytes were cotransfected with empty expression plasmid. Similarly, transduction of rat hepatocytes with a recombinant adenovirus expressing PPAPDC2 enhanced SQ1-mediated CYP2B1 mRNA induction by 1.4-fold over the induction that was seen in hepatocytes transduced with control adenovirus. Cotransfection with a short hairpin RNA targeting PPAPDC2 reduced SQ1-mediated CAR activation by approximately 80% relative to the activation that occurred in hepatocytes transfected with nontargeting short hairpin RNA. These results indicate that PPAPDC2 plays an important role in SQ1-mediated CAR activation, most likely by catalyzing the conversion of FPP to farnesol.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26700959      PMCID: PMC4767380          DOI: 10.1124/dmd.115.068437

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  19 in total

Review 1.  Regulation of the mevalonate pathway.

Authors:  J L Goldstein; M S Brown
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

2.  Regulation of rat hepatic cytochrome P450 expression by sterol biosynthesis inhibition: inhibitors of squalene synthase are potent inducers of CYP2B expression in primary cultured rat hepatocytes and rat liver.

Authors:  T A Kocarek; J M Kraniak; A B Reddy
Journal:  Mol Pharmacol       Date:  1998-09       Impact factor: 4.436

3.  Modulation of hepatic and renal drug metabolizing enzyme activities in rats by subchronic administration of farnesol.

Authors:  Thomas L Horn; Lina Long; Michael J Cwik; Robert L Morrissey; Izet M Kapetanovic; David L McCormick
Journal:  Chem Biol Interact       Date:  2005-04-15       Impact factor: 5.192

4.  Farnesol as a regulator of HMG-CoA reductase degradation: characterization and role of farnesyl pyrophosphatase.

Authors:  T E Meigs; R D Simoni
Journal:  Arch Biochem Biophys       Date:  1997-09-01       Impact factor: 4.013

5.  Farnesol-derived dicarboxylic acids in the urine of animals treated with zaragozic acid A or with farnesol.

Authors:  R G Bostedor; J D Karkas; B H Arison; V S Bansal; S Vaidya; J I Germershausen; M M Kurtz; J D Bergstrom
Journal:  J Biol Chem       Date:  1997-04-04       Impact factor: 5.157

Review 6.  Protein prenylation: molecular mechanisms and functional consequences.

Authors:  F L Zhang; P J Casey
Journal:  Annu Rev Biochem       Date:  1996       Impact factor: 23.643

7.  Suppression of CYP2B induction by alendronate-mediated farnesyl diphosphate synthase inhibition in primary cultured rat hepatocytes.

Authors:  Nancy M Jackson; Thomas A Kocarek
Journal:  Drug Metab Dispos       Date:  2008-07-10       Impact factor: 3.922

Review 8.  Mevalonate pathway: a review of clinical and therapeutical implications.

Authors:  Irina Buhaescu; Hassane Izzedine
Journal:  Clin Biochem       Date:  2007-03-31       Impact factor: 3.281

9.  Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A.

Authors:  S Vaidya; R Bostedor; M M Kurtz; J D Bergstrom; V S Bansal
Journal:  Arch Biochem Biophys       Date:  1998-07-01       Impact factor: 4.013

10.  Identification and functional characterization of a presqualene diphosphate phosphatase.

Authors:  Koichi Fukunaga; Makoto Arita; Minoru Takahashi; Andrew J Morris; Michael Pfeffer; Bruce D Levy
Journal:  J Biol Chem       Date:  2006-02-07       Impact factor: 5.157

View more
  1 in total

1.  Differential Regulation of Gene Expression by Cholesterol Biosynthesis Inhibitors That Reduce (Pravastatin) or Enhance (Squalestatin 1) Nonsterol Isoprenoid Levels in Primary Cultured Mouse and Rat Hepatocytes.

Authors:  Elizabeth A Rondini; Zofia Duniec-Dmuchowski; Daniela Cukovic; Alan A Dombkowski; Thomas A Kocarek
Journal:  J Pharmacol Exp Ther       Date:  2016-05-25       Impact factor: 4.030

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.